Skip to content

Benjamin Victor Ineichen

Center for Reproducible Science and Research Synthesis, University of Zurich, Zurich, Switzerland. benjamin.ineichen@unibe.ch.

2 papers in the library · 3 citations · publishing 2025

Papers

The translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies.

Translational psychiatry October 10, 2025 Wolfgang Emanuel Zürrer, Lionel Wettstein, Helena D Aicher et al. 3 citations

Salvinorin A, the main psychoactive compound in Salvia divinorum, shows therapeutic potential for pain, addiction, and stroke in animal models, but its side effects—including anxiety, motor and cognitive impairment—may limit clinical use. A systematic review and meta-analysis of 82 studies found anti-nociceptive, anti-inflammatory, neuroprotective, and anti-addictive effects, though depression results were inconsistent. Doses ranged from 0.1 to 10 mg/kg, with rapid onset and a half-life of about one hour. Sixteen structurally distinct analogues were identified with potentially improved safety and pharmacokinetic profiles. Findings support further development of analogues to overcome the side effect profile.

The translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies

Universität Zürich, ZORA October 10, 2025 Wolfgang Emanuel Zürrer, Lionel Wettstein, Helena Aicher et al.

Salvinorin A, the main psychoactive compound in Salvia divinorum and a potent kappa opioid receptor agonist, has been tested in animal models of pain, stroke, addiction, and depression. It shows anti-nociceptive, anti-inflammatory, neuroprotective, and anti-addictive effects. However, findings on depression are inconsistent, with both antidepressant and depressogenic outcomes reported. Toxicity data indicate anxiogenic effects and motor and cognitive impairment, with minimal impact on vital parameters. Pharmacokinetic data show rapid onset, fast peak, and a half-life of about one hour. Sixteen structurally distinct analogues were identified with potentially improved safety and pharmacokinetic profiles.